As another example, denosumab, a humanized monoclonal antibody against RANKL designed to inhibit bone resorption by binding to RANKL, was shown to increase bone mineral density and significantly inhibited the progression of bone erosion in rheumatoid arthritis patients in a randomized controlled trial. This evidence concerns the gene TNFSF11 and rheumatoid arthritis.